Treatment of Mucinous Adenocarcinoma of the Appendix
Clinical Scenario
Mucinous adenocarcinoma of the appendix (MAA) is recognised as a biologically and histologically distinct entity — separate from colorectal cancer and from colonic-type adenocarcinoma of the appendix. Management is guided by the histologic type and the extent of disease at presentation.
Treatment Approach (Partial)
When peritoneal dissemination is present, the evidence-based approach centres on complete surgical cytoreduction combined with intraperitoneal (IP) chemotherapy — a combined locoregional strategy that addresses both surgical and pharmacologic disease control.
Full regimen details, agent selection, and procedure specifics are in the structured protocol →
References
- Mucinous adenocarcinoma of the appendix (MAA) appears to be a biologically and histologically distinct entity from colorectal cancer and from colonic-type adenocarcinoma of the appendix.
- Management of MAA is dependent on the histologic type and the extent of disease at presentation, and is outlined in Fig. 3.
- The optimal therapy is complete surgical cytoreduction (defined as removal of all gross disease or reduction of tumor deposits to 2.5 mm in thickness) in combination with IP chemotherapy.
- Cytoreduction routinely involves complete omentectomy and right lower quadrant peritonectomy.
- Bilateral oophorectomy is also recommended, especially in postmenopausal women, as the ovaries are a frequent site of metastasis and recurrence if not removed.
DOI: 10.1055/s-0035-1564433
View source ↗